Recurring Revenue From Stem Cell BankingThe Cellaviva stem cell banking business provides contract-based, fee-for-service revenue that is relatively steady versus R&D cycles. This recurring service income creates a predictable cash inflow stream that partially offsets development volatility and supports ongoing operations and patient-facing capabilities over the medium term.

Debt-free Balance SheetA zero-debt position materially reduces interest and refinancing risk, granting strategic flexibility to prioritise R&D or commercial investments. Over a 2–6 month horizon this lowers solvency pressure, improves optionality for partnering or timed capital raises, and preserves cash for operational needs relative to leveraged peers.

Owned R&D Asset With Partnership Upside (ProTrans)ProTrans represents a structural value driver: as an allogeneic MSC therapy it can produce milestone and royalty streams if partnered or licensed. Clinical progress or a deal would convert R&D investment into scalable revenues, offering asymmetric upside that remains relevant beyond short-term market moves.

Bears Say

Persistent Negative Cash FlowSustained large negative operating and free cash flow steadily depletes reserves and forces reliance on external funding. Over the medium term this increases dilution risk, constrains discretionary investment, and may compress runway for clinical programs and commercial growth unless operating performance or financing changes materially.

Ongoing Heavy Losses And Negative MarginsNegative gross profit implies core revenues do not cover direct costs, not just SG&A or R&D. Deeply negative operating and net margins signal structural unprofitability that, if persistent, will erode capital and limit ability to scale. Achieving sustainable margins requires either meaningful revenue growth or material cost restructuring.

Shrinking Equity Base Raises Funding VulnerabilityA materially reduced equity base weakens the balance sheet buffer against losses, increasing the likelihood of dilutive equity raises or unattractive financing terms. Combined with ongoing cash burn, the smaller equity cushion raises execution risk and may impair negotiating leverage for partnerships or licensing deals.

65G FAQ

What was NextCell Pharma AB’s price range in the past 12 months?

NextCell Pharma AB lowest stock price was €0.05 and its highest was €0.28 in the past 12 months.

What is NextCell Pharma AB’s market cap?

NextCell Pharma AB’s market cap is €13.27M.

When is NextCell Pharma AB’s upcoming earnings report date?

NextCell Pharma AB’s upcoming earnings report date is May 28, 2026 which is in 79 days.

How were NextCell Pharma AB’s earnings last quarter?

NextCell Pharma AB released its earnings results on Oct 30, 2025. The company reported -€0.007 earnings per share for the quarter, beating the consensus estimate of -€0.009 by €0.002.

Is NextCell Pharma AB overvalued?

According to Wall Street analysts NextCell Pharma AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does NextCell Pharma AB pay dividends?

NextCell Pharma AB does not currently pay dividends.

What is NextCell Pharma AB’s EPS estimate?

NextCell Pharma AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does NextCell Pharma AB have?

NextCell Pharma AB has 111,392,960 shares outstanding.

What happened to NextCell Pharma AB’s price movement after its last earnings report?

NextCell Pharma AB reported an EPS of -€0.007 in its last earnings report, beating expectations of -€0.009. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of NextCell Pharma AB?

Currently, no hedge funds are holding shares in DE:65G

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

NextCell Pharma AB

NextCell Pharma AB, a biopharmaceutical company, engages in the research and development of novel stem cell therapies in Sweden. The company develops ProTrans, a drug candidate comprising stem cells primarily for treating autoimmune and inflammatory diseases. It also provides Cellaviva, a stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue. NextCell Pharma AB was incorporated in 2014 and is based in Huddinge, Sweden.